RxDoctor Payments Data

Jack Collier, MD

Clinical Cardiac Electrophysiology · Oklahoma City, OKNPI 1043350275

Payments from drug & device makers

What this record shows

Boston Scientific accounts for 63.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $1,960 and has fallen 93.9% since, to $119 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in OK, where the typical reported total is $22,745.

$4,820in general payments, 2019–2025

Across 63 payments — averaging $76.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Medtronic$1K
  • Biosense Webster, Inc.$203
  • Pfizer$65
  • Irhythm Technologies, Inc.$31
  • Kestra Medical Technology Services, Inc.$25
  • plus $20 from 1 others
$31,317in research payments, 2019–2025

Across 29 payments — averaging $1079.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$31K

What the payments were for

  • Travel & lodging$2,74157%
  • Food & beverage$2,07943%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,820 in reported general payments places this provider in the 15th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.

See all clinical cardiac electrophysiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$399,410
Medicare patients
1,138
Services billed
5,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban841$758,949
Dofetilide899$159,358
XareltoRivaroxaban127$124,542
Flecainide Acetate138$5,670
Amiodarone Hcl182$4,055
Mexiletine Hcl26$3,402
Metoprolol Succinate176$3,044
SotalolSotalol Hcl91$2,531
Diltiazem 24hr Er (Cd)Diltiazem Hcl76$2,039
Potassium Chloride103$1,933
Digoxin60$1,054
Fludrocortisone Acetate24$868
ClopidogrelClopidogrel Bisulfate77$644
Metoprolol Tartrate58$598
Warfarin Sodium45$597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$758,949841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.

Other clinical cardiac electrophysiology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →